Monthly Archives: September 2014

Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014

Posted: September 12, 2014 at 7:44 am

San Antonio, TX (PRWEB) September 11, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational seminar about umbilical cord stem cell therapy on Saturday, September 20, 2014 in San Antonio, Texas at the La Cantera Hill Country Resort from 1:00 pm to 4:00 pm.

Stem Cell Institute Speakers include:

Neil Riordan PhD Umbilical Cord Stem Cell Clinical Trials for MS and Autism: Rationale and Clinical Protocols

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Umbilical Cord Stem Cell Therapy for Arthritis, Inflammation and Sports Injuries

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Special Guest Speaker:

Janet Vaughan, DDS, MS, Professional Dancer- Successful Stem Cell Therapy in Panama: A Patients Perspective

Dr. Vaughan is Board Certified in Orthodontics (Diplomate of the American Board of Orthodontics) and she is a Fellow in the International College of Dentistry.

Follow this link:
Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014

Posted in Stem Cell Therapy | Comments Off on Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014

Feds give Cellerant $47.5M for stem cell treatment that preps for nuclear disaster

Posted: September 12, 2014 at 7:44 am

Stem cell therapy is one way thegovernments preparing for a nationimpacted by nuclear disaster.

Cellerant Therapeutics has received $47.5 million from the government to develop its treatment for radiation poisoning. If approved, the feds could buy the drug for the Strategic National Stockpile, which is a part of Project Bioshield- a portion of the Bush-era War on Terror that medically readies the nation against chemical, biological, radiological or nuclear attacks.

This is part of a $163.8 million commitment from theBiomedical Advanced Research and Development Authority, or BARDA.

The new dollars will go toward San Carlos, California-based Cellerants Phase 2 trial in patients with acute myeloid leukemia, as well as the preclinical trials to treat radiation poisoning, or Acute Radiation Syndrome.

As it relates toradiation poisoning, Cellerant said its drugCLT-008 is meant to provide hematopoietic support after exposure to ionizing radiation such as from a nuclear or radiological weapon, or from a nuclear accident, it said in a statement.

The privately held company also recently wrapped up early-stage clinical studies in patients with acute myeloid leukemia, as well as in patients that are undergoing an umbilical cord blood transplant. Cellerant found CLT-008, was safely tolerated in 75 patients, it said in a statement. Its Phase 2 is testing for a decrease in risk of febrile neutropenia, and infections stemming from chemo.

CLT-008 is essentially a collection of deep-freezed stem cells that can ultimately defrost and mature into working granulocytes, platelets and red blood cells in a person. In nonclinical models, Cellerant has shown that the treatments highly effective in providing protection from lethal radiation, preventing infection, facilitating stem cell engraftment and improving overall survival.

Get our daily newsletter or follow us.

Please enter your email below:

View original post here:
Feds give Cellerant $47.5M for stem cell treatment that preps for nuclear disaster

Posted in Cell Therapy | Comments Off on Feds give Cellerant $47.5M for stem cell treatment that preps for nuclear disaster

Cancer Survivor Saved by Measles Virus Raises Funds for Expanded Trial

Posted: September 12, 2014 at 3:59 am

Watch more news videos | Latest world newsCopy

After battling blood cancer for 10 years, Stacy Erholtz has no signs of the disease, thanks to an experimental treatment that used an engineered version of the measles virus.

Now, a year after finishing her treatment, the 50-year-old mother of three is transitioning from patient to advocate, working with the Rochester, Minnesota-based Mayo Clinic to expand the tiny trial that saved her life.

"When I was first diagnosed, there was not a lot of options. We strung together 10 years of life with a disease that is typically done in three to five," said Erholtz, who had tumors on her forehead, color bone, sternum and spine from multiple myeloma before the last-ditch treatment. "I'm encouraged. I want people to join me in remission right now."

Would You Volunteer to Get the Flu for $3,000?

Three Things You Should Know About Measles

Mom Whose Child Died After Contracting Chickenpox Advocates for Vaccines

Multiple myeloma is a type of blood cancer that affects the immune system, according to the Mayo Clinic. It can cause kidney-failure.htm" id="ramplink_kidney failure_" target="_blank">kidney failure, bone fractures and repeated infections.

After chemotherapy and stem cell transplants failed, Erholtz was accepted into the measles trial and given the highest possible dose of the engineered virus, which was designed to attack her cancer cells and leave her healthy cells alone, according to her physician, Dr. Stephen Russell.

"It's been adapted, so that it learned in the lab how to grow pretty efficiently on myeloma cells, "said Russell, who is in charge of the new trial. "It's lost the ability to cause harm on normal cells."

Original post:
Cancer Survivor Saved by Measles Virus Raises Funds for Expanded Trial

Posted in Minnesota Stem Cells | Comments Off on Cancer Survivor Saved by Measles Virus Raises Funds for Expanded Trial

Stem cells help researchers understand how schizophrenic brains function

Posted: September 12, 2014 at 3:57 am

PUBLIC RELEASE DATE:

11-Sep-2014

Contact: Mary Beth O'Leary moleary@cell.com 617-397-2802 Cell Press @CellPressNews

Using human induced pluripotent stem cells (hiPSCs), researchers have gained new insight into what may cause schizophrenia by revealing the altered patterns of neuronal signaling associated with this disease. They did so by exposing neurons derived from the hiPSCs of healthy individuals and of patients with schizophrenia to potassium chloride, which triggered these stem cells to release neurotransmitters, such as dopamine, that are crucial for brain function and are linked to various disorders. By discovering a simple method for stimulating hiPSCs to release neurotransmitters, the findings in the International Society for Stem Cell Research's journal Stem Cell Reports, published by Cell Press, could provide new insights into how neurons communicate with each other and could lead to a better understanding of the neural mechanisms underlying a range of brain disorders.

"This study is novel because it shows that stem cell neurons derived from patients can provide new insight into neurotransmitter mechanisms occurring in brain disorders such as schizophrenia," says senior study author Vivian Hook of the University of California, San Diego. "The approach of this study has broad opportunities for uncovering the neurochemistry of brain cell communication in numerous brain disorders, via these studies of human disease in a dish. Findings from these studies will lead to new therapeutic strategies for brain disorders, especially those mental and neurological diseases for which no drug treatments exist today."

hiPSCS are cells that are taken from adults, genetically reprogrammed to an embryonic stem cell-like state, and then converted into specialized cells such as neurons. Patient-derived hiPSCs offer the possibility of modeling an individual's disease in a dish and assessing which drugs will most effectively treat the disease. Because dysfunction in neural communication is linked to brain disorders such as schizophrenia, Hook and Fred Gage of The Salk Institute and Kristen Brennand of the Icahn School of Medicine at Mount Sinai set out to determine whether hiPSC-derived neurons can be induced to release important brain signaling chemicals, allowing disease mechanisms to be studied in a dish.

To address this question, the researchers exposed hiPSC-derived neurons from healthy individuals and patients with schizophrenia to a chemical known to stimulate the release of neurotransmitters. They found that these cells contained neurotransmitter-producing enzymes and were capable of secreting dopamine, norepinephrine, and epinephrineneurotransmitters that are crucial for brain function and that are linked to various disorders. Moreover, secretion of the three neurotransmitters was enhanced in hiPSC-derived neurons from schizophrenia patients compared with those from healthy individuals.

"The significance of this study is that patient-derived stem cell neurons can uncover previously unknown neurotransmitter brain mechanisms occurring in schizophrenia," Hook says. "Because in vivo human brain research is limited, hiPSC neurons derived from patients create new opportunities to understand changes occurring in brain cells occurring in nervous system disorders. These approaches can potentially define new drug targets for the development of therapeutic agents to improve the lives of schizophrenia patients."

###

Stem Cell Reports, Hook et al.: "Human iPSC Neurons Display Activity-Dependent Neurotransmitter Secretion: Aberrant Catecholamine Levels in Schizophrenia Neurons."

Read more:
Stem cells help researchers understand how schizophrenic brains function

Posted in California Stem Cells | Comments Off on Stem cells help researchers understand how schizophrenic brains function

New Drug Study Offers Promise of Brain Cell Regeneration for Alzheimers Patients

Posted: September 11, 2014 at 8:57 am

Boston, MA (PRWEB) September 11, 2014

A promising first-in-class drug that stimulates the creation of new nerve cells in the brains of "Alzheimer's mice," will soon be tested in the brains of human patients with the promise it can help people in the early stages of the disease.

New research by Dr. Sam Gandy of Mount Sinai School of Medicine in New York and recently published in the journal Molecular Psychiatry outlines the extraordinary promise of the drug, known as an "mGluR2/3 blocker."

The learning behavior of Alzheimer's mice being treated with the mGluR2/3 blocker has been sustained at normal levels, Gandys study has revealed, in contrast to the steady decline of mice not being treated.

"It's extraordinary that, in such a short time, we have moved from ordinary skin cells to induced pluripotent stem cells in a Petri dish, to lab-generated human nerve cells, and now to a drug that could potentially create those cells inside a human brain," said Gandy.

"We realize that we are unlikely to have much impact in late stage Alzheimer's, but we are cautiously hopeful that this drug might arrest Alzheimer's disease at an early stage so that patients can remain functional for more extended periods."

The drug originally caught the attention of Gandy and his team for its possible ability to inhibit production of the toxic amyloid beta 42, associated with Alzheimer's disease. Created by the Japanese pharmaceutical firm Taisho and originally studied for depression, the drug acts by stimulating stem cells in the hippocampus to divide and form new nerve cells.

With funding from Cure Alzheimer's Fund, Gandys team conducted a pilot study of the drug's effects on a particular strain of mice. That study produced such promising results that it has drawn $1 million in funding from the Veterans Administration "MERIT Review" program that supports Gandy's lab at the James J. Peters VA Medical Center in the Bronx. The Louis B. Mayer Foundation and the Sarah and Gideon Gartner Foundation provided additional funding.

The mGluR2/3 blocker has also been administered to healthy young human subjects, and so far has seen to be safe. The next step for Gandy's team will be to treat elderly human subjects with the drug to test safety in this population before gearing up to test the drug in Alzheimer's patients.

The mGluR2/3 blocker is one of the few drugs being researched that holds promise for repairing brains damaged by neurodegenerative disease.

Link:
New Drug Study Offers Promise of Brain Cell Regeneration for Alzheimers Patients

Posted in New York Stem Cells | Comments Off on New Drug Study Offers Promise of Brain Cell Regeneration for Alzheimers Patients

Board of Regents candidates offer their opinions

Posted: September 11, 2014 at 8:56 am

University of Nebraska Board of Regents candidates Steve Glenn and Rob Schafer squared off in a forum hosted by the Beatrice Area Chamber of Commerce Tuesday night.

The two fielded 30 minutes of questions about everything from agriculture and accreditation to stem cell research and the hunt for the next university president.

Glenn, a Pawnee City property owner and owner of seven businesses across Nebraska, said his campaign focus was on making college affordable for students and improving the teaching, outreach and research aspects of the university.

Schafer, an attorney in Beatrice, said his goal is to make the university a worldwide leader in agriculture.

In April 2011, the University of Nebraska lost its accreditation with the American Association of Universities. The candidates were asked how they would help the university regain accreditation.

Schafer said a large part of the reason for losing accreditation was because the AAU did not include the University of Nebraska Medical Center in its assessment because of its distance from the UNL campus.

What I would like to see happen is that we be able to change how they determine membership so that we can include all the research, not just at the University of Nebraska Medical Center and the University of Nebraska-Lincoln campus, but also the University of Nebraska-Omaha and Kearney campuses as well as Curtis, Schafer said.

Glenn said the university planned very poorly.

There are very specific metrics that define membership in the AAU and we did not look at those metrics and say, How do we plan and aggressively deal with that? Glenn said. We have to build a very specific plan that should be in writing, the metric should be defined and that should be held accountable for our administration.

The two both said lowering student debt upon graduation is part of the reason they are running for the Board of Regents, even though the position comes without a salary or benefits other than free football tickets.

More here:
Board of Regents candidates offer their opinions

Posted in Nebraska Stem Cells | Comments Off on Board of Regents candidates offer their opinions

Renewing Organs – Video

Posted: September 11, 2014 at 8:49 am


Renewing Organs
Stem cell scientist Norman Iscove describes the power of stem cells to regenerate all kinds of cells and organs.

By: stemcellfoundation

See the original post here:
Renewing Organs - Video

Posted in Stem Cell Videos | Comments Off on Renewing Organs – Video

Programme Your BODY & MIND to REVERSE AGING with Stephen Hawking on Science Channel – Video

Posted: September 11, 2014 at 8:49 am


Programme Your BODY MIND to REVERSE AGING with Stephen Hawking on Science Channel
"STEM CELL UNIVERSE" with Stephen Hawking Stephen Hawking, Science Channel presents a controversial and groundbreaking new special STEM CELL UNIVERSE with Stephen Hawking premiering on Monday,...

By: Tricia Kwa

Here is the original post:
Programme Your BODY & MIND to REVERSE AGING with Stephen Hawking on Science Channel - Video

Posted in Stem Cell Videos | Comments Off on Programme Your BODY & MIND to REVERSE AGING with Stephen Hawking on Science Channel – Video

Jeunesse Anti Aging Skin Care Before and After Results – Video

Posted: September 11, 2014 at 8:49 am


Jeunesse Anti Aging Skin Care Before and After Results
http://skincarebusiness.co/ http://skincare.mybigcommerce.com/ The science of stem cells Dr. Nathan Newman, a world-renowned dermatologist and cosmetic surgeon, began searching for a topical...

By: Skin Care and Anti Aging Supplements

Read the original post:
Jeunesse Anti Aging Skin Care Before and After Results - Video

Posted in Stem Cell Videos | Comments Off on Jeunesse Anti Aging Skin Care Before and After Results – Video

PhytoScience Double Stem Cell and Tripl3 Stem Cell – Video

Posted: September 11, 2014 at 8:49 am


PhytoScience Double Stem Cell and Tripl3 Stem Cell
made from Apple , Grape , and Argan stem cells it has successfully achieved a human anti-aging treatment. from the award winning PhytoCellTec of 2008 now available in the Philippines.

By: whoamitojesus

Read more here:
PhytoScience Double Stem Cell and Tripl3 Stem Cell - Video

Posted in Stem Cell Videos | Comments Off on PhytoScience Double Stem Cell and Tripl3 Stem Cell – Video